succinylacetone has been researched along with Experimental Neoplasms in 1 studies
succinylacetone: inhibitor of heme biosynthesis
4,6-dioxoheptanoic acid : A dioxo monocarboxylic acid that is heptanoic acid in which oxo groups replace the hydrogens at positions 4 and 6. It is an abnormal metabolite of the tyrosine metabolic pathway and a marker for type 1 tyrosinaemia.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, F | 1 |
| Li, J | 1 |
| Deng, H | 1 |
| Wang, Y | 1 |
| Lei, C | 1 |
| Wang, Q | 1 |
| Xiang, J | 1 |
| Liang, L | 1 |
| Xia, J | 1 |
| Pan, X | 1 |
| Li, X | 1 |
| Long, Q | 1 |
| Chang, L | 1 |
| Xu, P | 1 |
| Huang, A | 1 |
| Wang, K | 1 |
| Tang, N | 1 |
1 other study available for succinylacetone and Experimental Neoplasms
| Article | Year |
|---|---|
GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diethylnitrosamine; Down-R | 2019 |